RxDoctor Payments Data

Gautam Ganguly, MD

Neurology · Whittier, CANPI 1215912522

Payments from drug & device makers

$10,257in general payments, 2019–2025

Across 375 payments — averaging $27.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Argenx US, Inc.$2K
  • UCB, Inc.$1K
  • AbbVie$1K
  • Novartis$1K
  • Lilly USA, LLC$319
  • Biogen$316
  • plus $4K from 41 others

What the payments were for

  • Consulting fees$1,43814%
  • Food & beverage$8,63084%
  • Education$1902%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,257 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$91,434
Medicare patients
616
Services billed
2,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate13$163,672
GilenyaFingolimod Hcl13$135,240
AubagioTeriflunomide11$99,194
AmpyraDalfampridine13$54,233
RytaryCarbidopa/Levodopa22$35,764
Nurtec OdtRimegepant Sulfate17$32,863
VimpatLacosamide13$17,836
RexultiBrexpiprazole12$15,578
BotoxOnabotulinumtoxina13$11,066
Levetiracetam201$9,123
Memantine Hcl187$7,051
Carbidopa-LevodopaCarbidopa/Levodopa151$6,341
Lacosamide43$5,984
Rasagiline Mesylate22$4,402
Gabapentin202$4,016

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$293$163,67213 claims
NovartisGilenya$1,072$135,24013 claims
SanofiAubagio$55$99,19411 claims
Acorda Therapeutics, IncAmpyra$108$54,23313 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$79$37,36038 claims
PfizerNurtec Odt$188$32,86317 claims
UCB, Inc.Vimpat$1,284$17,83613 claims
Otsuka America Pharmaceutical, Inc.Rexulti$74$15,57812 claims
AbbVieBotox$1,191$11,06613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in Whittier

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →